ClickCease FDA Meets To Discuss Device Approval | Law Blog
04/28/09   |   By

FDA Meets To Discuss Device Approval | DC Metro Area Medical Malpractice Law Blog

5 stars

Posted by: Salvatore J. Zambri, Esquire

The New York Times reported recently that the Food and Drug Administration (FDA) will conduct a rare meeting to discuss its device division, which is responsible for–among other things–evaluating, monitoring, and regulating medical devices.  According to the report, Dr. Donna-Bea Tillman, the agency’s director of device evaluation, called an “all-hands” meeting.  This comes in response to a letter from nine scientists who have written President Obama, charging that some in the agency have acted illegally, exposing the public to harmful, even deadly, products.

In the letter to President Obama, the scientists claimed that the device center inappropriately approved imaging studies designed to detect breast cancer and also allowed hospitals to wash and reuse device that were designed as single-use products, among other things.  Congress instituted an investigation into the charges. In January, the Government Accountability Office released a report that criticized the device center.

We hope that the FDA will seriously evaluate its deficiencies and make the changes that are necessary to protect the public from dangerous devices.

For information about defective devices and your legal rights, please click here or contact us at Regan Zambri & Long, PLLC at (202) 463-3030.

Regan Zambri Long
Posted In
Public Health
Share This Article
Tagged ,

Schedule a Free Consultation

Have you or your loved one sustained injuries in Washington DC, Maryland or Virginia? Regan Zambri Long PLLC has the best lawyers in the country to analyze your case and answer the questions you may have.

Call 202-960-4596

  • Please do not send any confidential or sensitive information in this form. This form sends information by non-encrypted email, which is not secure. Submitting this form does not create an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.

Back to Top